Quantum BioPharma Ltd C.QNTM

I see the website is updated

[DavidRosenberg]

https://fsdpharma.com/about-us/

FSD Pharma Growth Strategy

• Pursue further acquisition targets or potential investments that are unique and align with our mission of Total Brain Health
• Begin the process of advancing clinical trials for its compound Lucid-21-302, for the novel treatment of progressive MS (Multiple Sclerosis)
• Begin the process of advancing clinical trials for the treatment of depression, anxiety and psychiatric disorders through its psychedelic molecule Lucid-201
• Assess the best path forward for the advancement of FSD-201
• Complete the sale of our Cobourg property to increase cash in a non-dilutive method

Lucid Acquisition

• • • FSD Pharma acquired Lucid in September 2021
    • Two pre-clinical lead drug candidates aimed to treat neurodegenerative diseases and neuropsychiatric disorders

    oLUCID-21-302 – target treatment: Multiple Sclerosis

    oLUCID-201 – target treatment: depression & anxiety

    • New Chemical Entities (NCEs) licensed from UHN (largest healthcare research organization in NA) and uniquely paired with psychedelics formulations to improve patient outcomes
    • Large addressable markets: $23 Billion multiple sclerosis market and growing $225 Billion mental health market

FSD-201: Ultra Micro-PEA Compound

• Proprietary ultra micro-PEA formulation enhances the anti-inflammatory properties of PEA, a fatty acid amide currently used as a dietary supplement, by increasing its bioavailability and efficacy- making it suitable to treat a range of inflammatory conditions
• Holds exclusive worldwide licensing rights (except Italy & Spain) to ultra micro-PEA for all conditions in all regulatory categories
• Strong IP portfolio covering ultra-micronized composition of matter and use (2029-34 U.S. expiration)

Lead candidate (FSD 201- 600mg ultra micro-PEA)

Successfully completed Phase 1 first-in-human safety and tolerability trial. No serious adverse effects discovered

Toxicology trials have been completed and the results are being compiled

• Potential Target indications for Phase 2 trials currently being analyzed

Opioid replacement and/or sparing agent

Growing Market Opportunity in Psychedelics

• Growing body of research that suggests Psychedelics have the potential to treat a variety of neuropsychiatric disorders such as PTSD, depression, specifically complex TRD and MDD, and anxiety

FDA approval of Johnson & Johnson’s SPRAVATO (esketamine) for treatment-resistant depression

Meaningful MAPS Ph2 clinical data on MDMA-assisted psychotherapy for PTSD treatment

Expanding pipeline of psychedelic-based therapies

• $225B annual spend for mental health in the U.S.

Comparable Companies

as of September 27, 2021